Bukwang Pharmaceutical Co., Ltd.

As of June 30, 2026, Bukwang Pharmaceutical Co., Ltd. carries a market capitalization of 422.28B, placing it among publicly traded companies globally. Its enterprise value stands at 334.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Bukwang Pharmaceutical Co., Ltd. has 98.66M shares outstanding.

As of June 30, 2026, Bukwang Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 53.21. The price-to-sales ratio is 2.17, and the price-to-book ratio stands at 1.26.

As of June 30, 2026, Bukwang Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 22.86 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 28.68 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 334.11B versus a market cap of 422.28B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bukwang Pharmaceutical Co., Ltd. maintains a current ratio of 2.33, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Bukwang Pharmaceutical Co., Ltd. posted a return on equity (ROE) of 3.01, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 2.07, measuring how efficiently the asset base is converted into earnings. The company generates approximately 339.80M in revenue per employee across its workforce of 633.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.35 indicates how many times Bukwang Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bukwang Pharmaceutical Co., Ltd. recorded an income tax benefit of -568.54M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 8.13B, leaving 8.78B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Bukwang Pharmaceutical Co., Ltd.'s stock has gained approximately 6.15% over the past 52 weeks. The 50-day moving average sits at 4,083.40, while the 200-day moving average is 4,890.53.

Over the twelve months ended June 30, 2026, Bukwang Pharmaceutical Co., Ltd. generated 215.09B in revenue and converted that into 8.78B in net income, yielding earnings per share of 79.72. EBITDA reached 14.61B, while operating income came in at 11.65B.

As of June 30, 2026, Bukwang Pharmaceutical Co., Ltd. holds 169.10B in cash and equivalents against 80.67B in total debt, resulting in a net debt position of -24.28B. Total book value stands at 334.13B, with working capital of 152.13B providing operational flexibility.

Bukwang Pharmaceutical Co., Ltd. produced 5.48B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9.72B in capital expenditures, free cash flow totaled -4.24B - equivalent to -38.85 per share.

Over the twelve months ended June 30, 2026, Bukwang Pharmaceutical Co., Ltd. posted a gross margin of 44.46, reflecting its pricing power and cost economics. The operating margin of 5.42 and net profit margin of 4.08 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.91: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.15, meaning Bukwang Pharmaceutical Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Bukwang Pharmaceutical Co., Ltd.'s most recent stock split took place on May 30, 2025 with a 101:110 split ratio.

As of June 30, 2026, Bukwang Pharmaceutical Co., Ltd. has an Altman Z-Score of 3.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.